Ocular Therapeutix Company Profile (NASDAQ:OCUL)

Ocular Therapeutix trades on the NASDAQ under the ticker symbol "OCUL."

Ocular Therapeutix, Inc. (NASDAQ:OCUL) posted its quarterly earnings results on Tuesday, August, 8th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.59) by $0.05. The company earned $0.40 million during the quarter, compared to analysts' expectations of $0.51 million. Ocular Therapeutix had a negative return on equity of 101.03% and a negative net margin of 3,005.52%. The company's quarterly revenue was up .0% on a year-over-year basis. During the same period in the prior year, the business posted ($0.46) EPS. View Ocular Therapeutix's Earnings History.

Ocular Therapeutix is scheduled to release their next quarterly earnings announcement on Tuesday, November, 7th 2017. View Earnings Estimates for Ocular Therapeutix.

6 brokers have issued 12-month price objectives for Ocular Therapeutix's shares. Their forecasts range from $8.00 to $60.00. On average, they expect Ocular Therapeutix's share price to reach $24.00 in the next twelve months. View Analyst Ratings for Ocular Therapeutix.

Here are some recent quotes from research analysts about Ocular Therapeutix stock:

• 1. According to Zacks Investment Research, "Ocular Therapeutix, Inc. is a biopharmaceutical company. It is focused on the development and commercialization of ophthalmic therapeutic products using its proprietary hydrogel technology to address unmet or underserved needs in ophthalmology. The Company develops and markets eye care products. Ocular Therapeutix, Inc. is headquartered in Bedford, Massachusetts. " (5/23/2017)
• 2. Cantor Fitzgerald analysts commented, "We are initiating on Ocular Therapeutix with an Overweight rating and $35 Price target. We believe Ocular's portfolio of sustained release therapies have the potential to treat an array of ophthalmic conditions with significant unmet need. In focus, we view the upcoming FDA decision this year for lead developmental candidate DEXTENZA' in post-surgical ocular pain as a meaningful catalyst for the shares, and estimate that DEXTENZA could reach annual sales of $600 million at peak market penetration in 2023, with further growth to $900 million by 2030 for this indication alone in the U.S." (2/9/2017)

Some companies that are related to Ocular Therapeutix include Sientra (SIEN), Utah Medical Products (UTMD), Transenterix (TRXC), Transenterix (TRXC), T2 Biosystems (TTOO), SeaSpine Holdings Corporation (SPNE), Bioquell plc (BQE), Tandem Diabetes Care (TNDM), Capnia (SLNO), Surgical Innovations Group Plc (SUN), Alliqua BioMedical (ALQA), Cytori Therapeutics (CYTX), Lombard Medical (EVAR), NeuroMetrix (NURO), InspireMD (NSPR), CareFusion (CFN), Covidien Ltd (COV) and CRH Medical Corp (CRHM).

Ocular Therapeutix's management team includes the folowing people:

• Amarpreet Sawhney Ph.D., Executive Chairman of the Board
• James Fortune, Interim Principal Financial Officer, Chief Operating Officer, Interim Princiapl Accounting Officer
• George V. Migausky, Interim Chief Financial Officer
• Daniel M. Bollag Ph.D., Senior Vice President - Regulatory Affairs, Pharmacovigilance and Quality
• Andy Hurley, Chief Commercial Officer
• Jonathan Talamo M.D., Chief Medical Officer
• Jaswinder S. Chadha, Director
• W. James O'Shea, Director
• Jeffrey S. Heier M.D., Independent Director
• Richard L. Lindstrom M.D., Independent Director

Ocular Therapeutix's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Versant Venture Management LLC (7.63%), Jennison Associates LLC (6.84%), SV Health Investors LLC (5.53%), FMR LLC (4.56%), Vanguard Group Inc. (3.12%) and Columbus Circle Investors (1.99%). View Institutional Ownership Trends for Ocular Therapeutix.

Ocular Therapeutix's stock was sold by a variety of institutional investors in the last quarter, including Jennison Associates LLC, Columbus Circle Investors, Deltec Asset Management LLC, FMR LLC, JPMorgan Chase & Co., Edmond DE Rothschild Holding S.A., Wells Fargo & Company MN and NEXT Financial Group Inc. View Insider Buying and Selling for Ocular Therapeutix.

Ocular Therapeutix's stock was bought by a variety of institutional investors in the last quarter, including Cowen Inc., State Street Corp, Northern Trust Corp, Parametric Portfolio Associates LLC, Neuberger Berman Group LLC, State of Wisconsin Investment Board, Alliancebernstein L.P. and Voya Investment Management LLC. View Insider Buying and Selling for Ocular Therapeutix.

Shares of Ocular Therapeutix can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Ocular Therapeutix stock can currently be purchased for approximately $6.31.